A drug used for multiple sclerosis nearly halves the chance of developing severe coronavirus symptoms in hospitalised patients and may prevent deaths, a new trial has shown.
Covid patients at nine hospitals including Southampton General were given an inhaled version of the treatment interferon beta-1a and were twice as likely to recover within 14 days as those in the placebo arm of the trial, even though they were sicker to begin with.
